KNSA insider sold 303,865 shares recently; 42,000 more to be sold via cashless exercise

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) filing a Form 144 notifies the intended sale of 42,000 Class A ordinary shares on 09/29/2025 through Charles Schwab & Co., Inc. The shares were acquired the same day via an employee stock option exercise and will be sold in a broker-assisted cashless exercise, with the filing reporting an aggregate market value of $1,609,716 against ~43.47 million shares outstanding.

The filing also discloses prior sales by the same holder, Eben Tessari, totaling 303,865 shares sold across seven transactions from 07/14/2025 to 09/15/2025 for aggregate gross proceeds shown per trade. The notice is a required disclosure under Rule 144 and includes the signer’s representation there is no undisclosed material information.

Positive

• Compliance with Rule 144: Form 144 filed with required details for planned sale and recent transactions.
• Transaction transparency: Acquisition method (employee stock option exercise) and broker-assisted cashless exercise are disclosed.

Negative

• Substantial insider selling: 303,865 shares sold in the prior three months and an additional 42,000 shares planned, which may concern investors.
• Concentration of sales by one holder: Multiple large disposals by Eben Tessari over a short period could be interpreted negatively by the market.

Insights

Securities Analyst

TL;DR: Insider has sold substantial shares recently and plans another sale of 42,000 shares acquired via option exercise.

The filing documents a planned sale of 42,000 Class A shares with an indicated market value of $1.61 million and shows prior disposals totaling 303,865 shares over the prior three months. For a company with ~43.47 million shares outstanding, the recent three-month sales represent about 0.70% of outstanding shares and the new 42,000-share sale is ~0.10%. Such concentrated insider selling can weigh on market perception even if executed under Rule 144 compliance; however, the filing states the shares were acquired by employee option exercise and will be sold via broker cashless exercise, indicating routine liquidity actions rather than an off-market transfer.

Corporate Governance Expert

TL;DR: Disclosure appears complete under Rule 144; pattern of sales merits monitoring for governance signals.

The Form 144 provides required details: acquisition date, nature (employee option exercise), broker, sale date, and recent sales history by the same person. The signer affirms no undisclosed material information. From a governance perspective, repeated insider sales are noteworthy but the filing shows procedural compliance (cashless exercise, broker-assisted sale). Investors and monitors should note frequency and size of sales relative to holdings, though the document itself does not assert any undisclosed company-specific developments.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	42000	1609716.00	43472928	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	09/29/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			42000	09/29/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	07/14/2025	18900	542860.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/05/2025	138614	4602409.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/18/2025	16200	547070.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/03/2025	15091	535778.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/04/2025	85271	3028740.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/05/2025	13389	477497.00
Eben Tessari 100 Hayden Ave Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	09/15/2025	16400	598016.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for KNSA disclose about the planned sale?

The Form 144 discloses a planned sale of 42,000 Class A ordinary shares on 09/29/2025 through Charles Schwab, with an aggregate market value of $1,609,716.

How were the 42,000 shares acquired according to the filing?

The shares were acquired on 09/29/2025 via an employee stock option exercise, with payment handled by the broker in a cashless exercise.

How many shares has the insider sold in the past three months per this filing?

The filing lists seven sales from 07/14/2025 to 09/15/2025 totaling 303,865 shares by Eben Tessari, with gross proceeds reported per trade.

What percentage of outstanding stock do these sales represent?

Based on 43,472,928 shares outstanding, the prior three-month sales (~303,865 shares) represent about 0.70% and the planned 42,000-share sale is about 0.10% of outstanding shares.

Does the filing state any undisclosed material information about Kiniksa?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.